theory clinical_104_0
imports Main

begin

typedecl entity
typedecl event

consts
  Irreversible_Inhibitor :: "entity ⇒ bool"
  Targeted_To :: "entity ⇒ entity ⇒ bool"
  HER2_Kinase_Domain :: "entity ⇒ bool"
  Overcome :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Trastuzumab_Resistance :: "entity ⇒ bool"
  Induced_By :: "entity ⇒ event ⇒ bool"
  HER2_Activating_Mutation :: "event ⇒ bool"
  HER2_V777L :: "entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  Trastuzumab :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Bind :: "event ⇒ bool"
  Extracellular_Kinase_Domain :: "entity ⇒ bool"
  Mutation_In :: "event ⇒ bool"
  Intracellular_Kinase_Domain :: "event ⇒ bool"
  Targeting :: "entity ⇒ bool"
  HER_V777L_Mutation :: "entity ⇒ bool"
  Irreversible_Tyrosine_Kinase_Inhibitor :: "entity ⇒ bool"
  Treatment_Resistance :: "entity ⇒ bool"

(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. Irreversible_Inhibitor x ∧ Targeted_To x y ∧ HER2_Kinase_Domain y ∧ Overcome e1 ∧ Agent e1 x ∧ Trastuzumab_Resistance z ∧ Induced_By z e2 ∧ HER2_Activating_Mutation e2"

(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)
axiomatization where
  explanation_2: "∃x y z e1 e2 e3. HER2_V777L x ∧ Resistance y ∧ Trastuzumab z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Bind e2 ∧ Agent e2 z ∧ Extracellular_Kinase_Domain y ∧ Mutation_In e3 ∧ Intracellular_Kinase_Domain e3"

theorem hypothesis:
  assumes asm: "HER_V777L_Mutation y ∧ Treatment_Resistance y"
  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)
  shows "∃x e. Targeting x ∧ Irreversible_Tyrosine_Kinase_Inhibitor x ∧ Overcome e ∧ Agent e x ∧ Patient e y"
proof -
  (* From the premise, we have known information about HER_V777L_Mutation and Treatment_Resistance. *)
  from asm have "HER_V777L_Mutation y ∧ Treatment_Resistance y" by simp
  (* Explanation 1 provides a scenario where an irreversible inhibitor targeted to the HER2 kinase domain overcomes trastuzumab resistance induced by a HER2-activating mutation. *)
  (* We can relate this to the hypothesis by considering the targeting of the HER V777L mutation with an irreversible tyrosine kinase inhibitor. *)
  (* Explanation 2 indicates that HER2 V777L causes resistance to trastuzumab, which aligns with the treatment resistance in the premise. *)
  (* Therefore, targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor should overcome the treatment resistance. *)
  then have "∃x e. Targeting x ∧ Irreversible_Tyrosine_Kinase_Inhibitor x ∧ Overcome e ∧ Agent e x ∧ Patient e y" sledgehammer
  then show ?thesis <ATP>
qed

end
